PTEN and p53: Who will get the upper hand?  by Trotman, Lloyd C & Pandolfi, Pier Paolo
CANCER CELL : FEBRUARY 2003 · VOL. 3 · COPYRIGHT © 2003 CELL PRESS 97
Tumor suppressor genes are conceptual-
ly regarded as autonomous anti-cancer
units. Along this tenet, only their homozy-
gous loss would lead to cancer patho-
genesis (Knudson, 1971). At the cellular
level, however, autonomy appears to be a
remote concept since protein function
and gene expression are well regulated
through cooperating and antagonizing
networks. Therefore, linking the regulato-
ry mechanisms between tumor suppres-
sors is key to understanding, predicting,
and interfering with tumorigenesis. Given
that previous work has demonstrated
several layers of indirect crosstalk
between the two most highly mutated
tumor suppressors, p53 and PTEN, it
would have certainly been tempting to
speculate that PTEN also directly co-
operates with p53 in tumor suppression.
Mechanistically however, the role of
PTEN in tumor suppression has been
attributed to the cytoplasm while the site
of action of p53 is definitely ascribed to
the nucleus, thus rendering it problematic
to envision how this would occur.
According to a study published in this
issue of Cancer Cell (Freeman et al.,
2003), a direct functional crosstalk
between PTEN and p53 does indeed
exist, adding a novel twist to the emerg-
ing picture of the PTEN-p53 tumor
suppressor network.
The p53 tumor suppressor acts as a
transcription factor capable of regulating
the expression of target genes critical for
growth inhibition, cell senescence, and
induction of apoptosis in response to
DNA damage and oncogenic transfor-
mation (Sharpless and DePinho, 2002).
Cells are therefore extremely sensitive to
p53 levels and transcriptional activation.
In the absence of stress, levels of p53 in
normal cells are maintained low mostly
through its constant proteasome-depen-
dent degradation mediated by the mdm2
protein that acts as a p53 ubiquitin-
ligase. A number of p53 posttranslational
modifications that are subjected to a
dynamic and tight regulation including
phosphorylation, acetylation, and
sumoylation lead to its stabilization and
transcriptional activation upon cellular
stress. The extraordinary multilayered
complexity of the p53 regulatory network
and its central importance in tumor sup-
pression make it an ideal molecular plat-
form on which other tumor-suppressive
pathways could impinge.
PTEN (for phosphatase and tensin
homolog deleted on chromosome 10)
mutations and partial or complete loss
have been frequently reported in tumors
of various histological origins. PTEN is
also found mutated in three related
human autosomal dominant disorders
characterized by developmental defects
and high tumor susceptibility (Di
Cristofano and Pandolfi, 2000).
The PTEN gene encodes a dual
specificity phosphatase, which to some
surprise, however, has been shown to
primarily dephosphorylate the plasma
membrane lipid phosphatidyl-inositol-3-
phosphate (PIP3) whereas examples of
protein targets have remained rare.
Conversion of PIP3 to PIP2, however,
enables PTEN to effectively antagonize
the PI3 kinase pathway, resulting in inac-
tivation of the many PH domain-contain-
ing downstream protein kinases, most
notably Akt and PDK1 (Cantley, 2002),
which in turn act on a variety of proteins
to stimulate cell survival, proliferation,
growth, and migration.
In the mouse, complete Pten inactiva-
tion is embryonic lethal while Pten het-
erozygous mice co-develop, after a
latency period, multiple tumors of various
histological origins in complete agree-
ment with an important and pleiotropic
tumor suppressive role (Di Cristofano and
Pandolfi, 2000). In Pten heterozygous
mutants that have also lost one or both
copies of the p27KIP1 gene, encoding a cell
cycle inhibitor whose loss does not cause
an overt cancer phenotype, Pten-specific
tumors are markedly accelerated (Di
Cristofano et al., 2001). Most notably,
these tumors retain Pten expression, indi-
cating that its tumor-suppressive function
might be dose dependent, and Pten thus
haploinsufficient in certain tissues in com-
bination with loss of another tumor sup-
pressor. These findings underscored the
importance of establishing the regulatory
mechanisms governing PTEN protein lev-
els and activity as their tight regulation
may be critical for tumor suppression.
The first report to link PTEN and p53
on a molecular level showed direct bind-
ing of p53 to a site in the PTEN promoter
(Stambolic et al., 2001). On top of p53-
independent basal expression, DNA-
damaging events such as γ irradiation
resulted in a p53-dependent increase of
PTEN mRNA in several cell lines (Figure
1A, pathway 2). Moreover, in Pten null
mouse embryonic fibroblasts (MEFs),
p53-mediated apoptosis was impaired,
underscoring the potential importance of
Pten transactivation for this process.
Altogether, this report positioned p53
upstream of PTEN in the regulation of its
expression level.
However, it soon became apparent
that PTEN could also regulate p53 func-
tion through its ability to antagonize PI3
kinase since Akt phosphorylation con-
sensus sites were identified in mdm2,
one of the major negative regulators of
p53 (Mayo and Donner, 2001; Zhou et
al., 2001). Upon phosphorylation of
these sites, mdm2 translocated into the
cell nucleus to ubiquitinate p53, resulting
in its nuclear export and degradation.
Since PTEN phosphatase activity is the
major antagonist of Akt, it was therefore
tempting to speculate that PTEN would
prevent this p53 degradation pathway by
keeping Akt inactive and that PTEN
would therefore be an essential compo-
nent of the p53 response upon DNA
damage (Figure 1A, pathway 1). Indeed,
the effect of PTEN on p53-mediated
transcription was also soon reported
(Mayo et al., 2002). PTEN, but not a
phosphatase-dead mutant, was able to
produce a moderate increase of p53-
mediated transcription even in the pres-
ence of mdm2, indicating that PTEN by
antagonizing PI3 kinase can indirectly
protect p53 from the degradation path-
way. Importantly, the above findings sug-
gested that PI3 kinase inhibitors such as
Wortmannin could sensitize refractory
tumors with wt p53 to treatment with
p53-inducing drugs such as etoposide
by mimicking PTEN activity and thus
increasing p53 stability (see Figure 1B).
In a study appearing in this issue of
Cancer Cell (Freeman et al., 2003), the
PTEN-p53 crosstalk is taken a step fur-
ther by identifying a p53 binding domain
in PTEN. By performing GST-pulldown
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experiments with p53 deletion mutants,
the C terminus of p53 was found to bind
PTEN. These in vitro binding studies
could be confirmed by a series of co-
immunoprecipitations in both human cell
lines and in cells derived from a Pten
conditional mouse knockout model.
Intriguingly, on PTEN, the p53 binding
activity was mapped to the C2 domain,
which so far had only been implicated in
stabilizing and properly positioning the
catalytic phosphatase domain of PTEN
at the plasma membrane (Georgescu et
al., 2000; Lee et al., 1999). This finding
led the authors to ask whether PTEN
might regulate p53 activity independent-
ly of its enzymatic activity. The results
indicate that phosphatase-dead mutants
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Figure 1. Functional crosstalk between PTEN and p53 and its therapeutic implications
A: PTEN and p53 interact on three levels.
1: The PTEN phosphatase inhibits activation of mdm2 by keeping Akt inactive. Akt, when activated through the PI3 kinase pathway, can phos-
phorylate cytoplasmic mdm2, resulting in its nuclear import. Nuclear mdm2 ubiquitinates p53 and targets it for proteasomal degradation in the
cytoplasm.
2: DNA damage results in a sharp increase of p53 protein which, in turn, can enhance PTEN transcription by binding to the PTEN promoter leading
to a positive feedback loop that protects p53 from degradation.
3: Pten binds to p53 resulting in increased p53 half-life. This interaction also stimulates p53-mediated transcription, although it is still unclear
whether PTEN participates in a p53-DNA complex. Cytoplasmic PTEN may also antagonize p53 degradation by cytoplasmic proteasomes.
Active or inactive forms of enzymes are denoted by an “a” or “i” superscript, respectively.
B: Tumor cells can be resensitized to DNA damage-inducing agents.
Tumor cells can be incapable of a p53 response in spite of having the functional protein because loss of, e.g., PTEN function results in increased
PI3 kinase activity. Thus, combination of DNA damage-inducing agents with PI3 kinase inhibitors can restore drug sensitivity.
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of PTEN are capable of stabilizing p53
as well. In half-life experiments, catalyti-
cally inactive PTEN could even protect
p53 from mdm2-independent degrada-
tion, indicating that it can counteract
additional mechanisms aimed at
degrading p53. In this respect, it could
be speculated that PTEN can also com-
pete with proteasomal degradation of
p53 in the cytoplasm (Figure 1A, path-
way 3). In human SAOS2 cells, it was
furthermore observed that protection did
not affect p53 mRNA levels, consistent
with degradation occurring at the protein
level. Next, the authors tested whether
the interaction with PTEN might sepa-
rately enhance p53-mediated transcrip-
tion. In transcription transactivation
assays adding back PTEN into Pten null
MEFs, an increase in p53-mediated
transcription could be observed in
agreement with the previous findings by
Mayo et al. However, in conflict with that
report, add back of a phosphatase-dead
PTEN mutant or the PTEN C2 domain
only still resulted in some stimulation of
p53 transactivation, consistent with a
role for direct interaction in p53 stabiliza-
tion. Given the multiple levels of
crosstalk, it is not yet clear whether
PTEN activates p53-mediated transcrip-
tion per se in addition to protecting it
from degradation. Also surprisingly, the
study could be carried out in MEF cells
that unexpectedly expressed high levels
of p53, while usually such p53 levels
have to be induced by DNA-damaging
agents. Results obtained by elec-
trophoretic mobility shift analysis left the
question of a PTEN-p53 complex on
DNA still open, while chromatin
immunoprecipitation experiments using
a p53 antibody and p21-specific primers
confirmed the notion that transfection of
PTEN independently of its enzymatic
activity may result in an increase of p53
levels, hence potentiating its function. To
assess the importance of Pten-p53
interactions in vivo, the authors made
use of a compound mutant mouse
model by crossing Pten and p53 knock-
out mutant mice. They found that in a
p53 heterozygous background, the sta-
tus of Pten was crucial since loss of just
one allele of Pten dramatically acceler-
ated tumor onset to the rate observed in
p53 null mice. Although mutations of the
remaining p53 and Pten alleles were not
formally excluded, these preliminary
results are in agreement with the
author’s observations in murine cell
lines. In summary, compelling experi-
mental evidence unraveling an intimate
functional crosstalk between PTEN and
p53 has been accrued in the past two
years. These findings are in agreement
with a recent observation made in
human breast cancers, demonstrating
that PTEN and p53 somatic mutations
are mutually exclusive and do not occur
in the same compartment (stroma ver-
sus epithelium) or in the same sample
(Kurose et al., 2002).
The study by Wu and colleagues rais-
es many important questions. It is not
presently clear how much a direct inter-
action with PTEN contributes to p53 sta-
bilization, nor is it known how PTEN
binding would lead to p53 stabilization. It
would also be interesting to determine
whether p53 modifications such as phos-
phorylation or ubiquitination affect it or if,
in turn, PTEN binding regulates these
posttranslational modifications. If PTEN
interacts with p53 in the cytoplasm
(Figure 1A, pathway 3) and whether this
regulates p53 nuclear import need also to
be assessed. This is of particular rele-
vance in view of the recent identification
of proteins such as PARC that actively
anchor p53 in the cytoplasm in the
absence of cellular stress (Nikolaev et al.,
2003). It also remains to be determined to
what extent p53-mediated apoptosis
depends on a direct PTEN-p53 interac-
tion. To this end, it will be important to
study whether cancer-associated muta-
tions of PTEN or p53 specifically interfere
with their interaction, which would firmly
establish the relevance of the novel find-
ing to human disease.
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